Search results for " Parkinson’s disease"

showing 10 items of 22 documents

Frequency and Correlates of Subjective Memory Complaints in Parkinson’s Disease with and without Mild Cognitive Impairment: Data from the Parkinson’s…

2018

Subjective memory complaints (SMC) may represent the preclinical phase of mild cognitive impairment (MCI) due to Alzheimer's disease. Dementia/MCI have been described with a high prevalence in Parkinson's disease (PD), but whether SMC may predict the development of cognitive impairment has been barely explored. To evaluate the frequency and clinical correlates of isolated SMC (PD-SMC) or within the construct of MCI in subjects with PD, 147 PD patients from the PArkinson's disease COgnitive impairment Study (PACOS) were consecutively recruited for the study. This is a multicenter study involving two Movement Disorder Centers in south Italy. All subjects underwent comprehensive neuropsycholog…

Male0301 basic medicineParkinson's diseaseParkinson's diseaseDiseaseNeuropsychological TestsAnxietyLogistic regressionExecutive Function0302 clinical medicineSurveys and QuestionnairesAttentionCognitive impairmentAged 80 and overGeneral NeuroscienceNeuropsychologyParkinson DiseaseGeneral MedicineMiddle Agedmusculoskeletal systemPsychiatry and Mental healthClinical PsychologyVisual Perceptioncardiovascular systemAnxietySettore MED/26 - NeurologiaFemaleAnxiety; cognitive impairment; disability; motor impairment; Parkinson's disease; subjective complaints; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental Healthmedicine.symptommedicine.medical_specialtyStatistics Nonparametricmotor impairment03 medical and health sciencesInternal medicinemental disordersmedicineHumansDementiaAgedRetrospective Studiescognitive impairmentSubjective complaints Cognitive Impairment Parkinson’s Disease Disability Motor Impairment AnxietyMemory DisordersNeuroscience (all)subjective complaintsbusiness.industrymedicine.diseaseCross-Sectional Studies030104 developmental biologydisabilityEtiologyGeriatrics and GerontologyCognition Disordersbusiness030217 neurology & neurosurgeryJournal of Alzheimer's Disease
researchProduct

Preliminary experience with a transcranial magnetic resonance-guided focused ultrasound surgery system integrated with a 1.5-T MRI unit in a series o…

2018

OBJECTIVETranscranial magnetic resonance–guided focused ultrasound surgery (tcMRgFUS) is one of the emerging noninvasive technologies for the treatment of neurological disorders such as essential tremor (ET), idiopathic asymmetrical tremor-dominant Parkinson’s disease (PD), and neuropathic pain. In this clinical series the authors present the preliminary results achieved with the world’s first tcMRgFUS system integrated with a 1.5-T MRI unit.METHODSThe authors describe the results of tcMRgFUS in a sample of patients with ET and with PD who underwent the procedure during the period from January 2015 to September 2017. A monolateral ventralis intermedius nucleus (VIM) thalamic ablation was pe…

MaleParkinson's diseaseMovement disordershigh-intensity focused ultrasound ablationIntraoperative Neurophysiological Monitoringmedicine.medical_treatmentinterventional030218 nuclear medicine & medical imagingMagnetic resonance guided focused ultrasound surgery0302 clinical medicineThalamusEssential tremorSettore MED/27 - NeurochirurgiaUltrasoundSettore MED/37 - NeuroradiologiaParkinson DiseaseGeneral MedicineMiddle AgedAblationMagnetic Resonance ImagingTreatment OutcomeNeuropathic painBBB = blood-brain barrier; ET = essential tremor; FRFSE = fast recalled FSE; FSE = fast spin echo; FSPGR = fast spoiled gradient echo; FTM = Fahn-Tolosa-Marin; HI-FU = high-intensity focused ultrasound; MRI; MRgFUS; MS = multiple sclerosis; PD = Parkinson’s disease; Parkinson’s disease; QUEST = Quality of Life in Essential Tremor; SWAN = susceptibility-weighted angiography; UPDRS = Unified Parkinson’s Disease Rating Scale; VIM = ventralis intermedius nucleus; brain; essential tremor; high-intensity focused ultrasound ablation; interventional; magnetic resonance–guided focused ultrasound surgery; stereotactic technique; tcMRgFUS = transcranial magnetic resonance–guided focused ultrasound surgerySettore MED/26 - NeurologiaFemaleRadiologymedicine.symptombrain; essential tremor; high-intensity focused ultrasound ablation; interventional; magnetic resonance-guided focused ultrasound surgery; mrgfus; mri; parkinson's disease; stereotactic techniqueMRIAdultmedicine.medical_specialtybrainEssential Tremormagnetic resonance–guided focused ultrasound surgery03 medical and health sciencesmedicineHumansmagnetic resonance-guided focused ultrasound surgeryUltrasonography InterventionalAgedThalamotomybusiness.industryMRgFUSmedicine.diseasestereotactic techniqueparkinson's diseaseParkinson’s diseaseSurgeryNeurology (clinical)businessSettore MED/36 - Diagnostica Per Immagini E Radioterapia030217 neurology & neurosurgeryFollow-Up StudiesNeurosurgical focus
researchProduct

Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease

2011

Mitochondrial dysfunction and oxidative stress occur in Parkinson’s disease (PD), but little is known about the molecular mechanisms controlling these events. Peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) is a transcriptional coactivator that is a master regulator of oxidative stress and mitochondrial metabolism. We show here that transgenic mice overexpressing PGC-1α in dopaminergic neurons are resistant against cell degeneration induced by the neurotoxin MPTP. The increase in neuronal viability was accompanied by elevated levels of mitochondrial antioxidants SOD2 and Trx2 in the substantia nigra of transgenic mice. PGC-1α overexpression also protected against MP…

MaleSOD2Mice TransgenicSubstantia nigraMitochondrionBiologyNeuroprotectionCell LineMiceCellular and Molecular Neurosciencechemistry.chemical_compoundDopaminemedicineAnimalsNeurotoxinParkinson Disease SecondaryMolecular BiologyPGC-1α RSV SIRT1 MPTP Dopaminergic neurons Parkinson’s diseasePharmacologyMPTPDopaminergicBrainParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaCell biologyDisease Models AnimalOxidative Stressnervous systemBiochemistrychemistry1-Methyl-4-phenyl-1236-tetrahydropyridineTrans-ActivatorsMolecular MedicineFemaleTranscription Factorsmedicine.drugCellular and Molecular Life Sciences
researchProduct

Sleep quality in caregivers of patients with Alzheimer’s disease and Parkinson’s disease and its relationship to quality of life

2012

ABSTRACTBackground: Knowledge about sleep complaints of caregivers of patients with Alzheimer's disease (AD) and Parkinson's disease (PD) is limited, and we lack information about the relationship between caregivers’ sleep problems and their quality of life (QoL).Methods: We evaluated subjective sleep quality and its relationship to QoL in a group of 80 caregivers of patients with AD (ADCG, n = 40) and PD (PDCG, n = 40), and in 150 controls. Information about night-time complaints was collected using the Pittsburgh Sleep Quality Index (PSQI). QoL was measured using the McGill QoL Questionnaire.Results: Eighteen ADCG (45%), 22 PDCG (55%), and 45 (30%) controls reported poor sleep quality. Me…

MaleSleep Wake DisordersCoping (psychology)medicine.medical_specialtyParkinson's diseaseDiseaseSleep Wake DisordersSeverity of Illness IndexPittsburgh Sleep Quality IndexCost of IllnessAlzheimer DiseaseSickness Impact ProfileSurveys and QuestionnairesSeverity of illnessMedicineHumansAgedAged 80 and overAlzheimer’s disease Parkinson’s disease neurodegenerative disorders caregivers sleep depression quality of lifebusiness.industryDepressionParkinson DiseaseMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologySleep deprivationCaregiversItalyPhysical therapyQuality of LifeRegression AnalysisSleep DeprivationFemaleSettore MED/26 - NeurologiaSelf ReportGeriatrics and Gerontologymedicine.symptomAlzheimer's diseasebusinessGerontologyStress Psychological
researchProduct

Prevalence of fatigue in Parkinson disease and its clinical correlates

2014

Objective: To assess in a noninterventional setting the prevalence and severity of fatigue in patients with Parkinson disease (PD). Methods: This was a cross-sectional study conducted in Italian patients with PD. Objectives included the evaluation of the current prevalence and severity of fatigue in patients with PD measured using the 16-item Parkinson Fatigue Scale (PFS-16), distressing fatigue (defined as a PFS-16 mean score $3.3), and assessment of its clinical correlates. Results: A total of 402 patients were enrolled and 394 patients completed the PFS-16 questionnaire with a PFS-16 mean (6SD) score of 2.87 6 0.99. Of these, 136 patients (33.8%) reported distressing fatigue (PFS-16 mean…

MaleTime FactorsDiseaseDSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th edition; ICD-10 5 International Classification of Diseases 10th revision; MAO-B 5 monoamine oxidase B; MS 5 multiple sclerosis; PD 5 Parkinson disease; PDQ-39 5 39-item Parkinson’s Disease Questionnaire; PDSS 5 Parkinson’s Disease Sleep Scale; PFS-16 5 16-item Parkinson Fatigue Scale; UPDRS 5 Unified Parkinson’s Disease Rating ScaleSeverity of Illness IndexQuality of life80 and overPrevalencePDSS 5 Parkinson’s Disease Sleep ScaleAge FactorDepression (differential diagnoses)FatigueAged 80 and overDepressionmusculoskeletal neural and ocular physiologyAge FactorsParkinson DiseasePDQ-39 5 39-item Parkinson’s Disease QuestionnaireMiddle AgedItalyPFS-16 5 16-item Parkinson Fatigue ScaleFemaleSettore MED/26 - NeurologiaMS 5 multiple sclerosiPsychologyHumanAdultSleep Wake Disordersmedicine.medical_specialtyPD 5 Parkinson diseasemacromolecular substancesArts and Humanities (miscellaneous)Internal medicinemedicineDistressingHumansIn patientAgedCross-Sectional StudieMAO-B 5 monoamine oxidase BUPDRS 5 Unified Parkinson’s Disease Rating Scalenervous system diseasesAdult; Age Factors; Aged; Aged 80 and over; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Neurology (clinical); Arts and Humanities (miscellaneous)Cross-Sectional Studiesnervous systemICD-10 5 International Classification of Diseases 10th revisionPhysical therapyNeurology (clinical)DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders 4th editionSleep Disorder
researchProduct

Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale

2020

Neurodegenerative diseases such as Alzheimer&rsquo

Proteomicsamyotrophic lateral sclerosisParkinson's diseaseDatabases FactualProteomeDiseaseComputational biologyBiologyPolymorphism Single NucleotideArticleTranscriptomeImmune systemHuntington's diseaseAlzheimer DiseasemedicineHumansbiochemistryAmyotrophic lateral sclerosislcsh:QH301-705.5GeneAlzheimer’s disease ; multi-omics ; neurodegeneration ; Huntington’s disease ; Parkinson’s disease ; amyotrophic lateral sclerosisNeurodegenerationneurodegenerationNeurodegenerative DiseasesParkinson DiseaseGenomicsGeneral Medicinemulti-omicsmedicine.diseaseImmunity HumoralGene OntologyHuntington Diseaselcsh:Biology (General)Parkinson’s diseaseTranscriptomeAlzheimer’s diseaseGenome-Wide Association StudyHuntington’s disease
researchProduct

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders

2022

(1) Background: Alpha-synuclein (α-syn) is a presynaptic neuronal protein that regulates several neuronal functions. In recent decades, the role of α-syn as a biomarker of neurodegenerative diseases has been explored, especially in synucleinopathies. However, only a few studies have assessed its role as biomarker in other neurological disorders. The aim of the study was to evaluate cerebrospinal fluid (CSF) α-syn levels in several neurological disorders; (2) Methods: We measured CSF α-syn levels by a commercial ELISA kit in 158 patients classified in the following group: controls, Alzheimer’s Disease (AD), cerebrovascular diseases, inflammatory central nervous …

Settore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinicanervous systemparkinson’s diseaseneurodegenerationCSF; biomarker; parkinson’s disease; alzheimer’s disease; neurodegenerationbiomarkerCSFalzheimer’s diseaseGeneral Medicinenervous system diseasesJournal of Clinical Medicine
researchProduct

Electrophysiological correlates of time discrimination in Parkinson's Disease

2011

Time perception Parkinson’s disease
researchProduct

Formation of covalent di-tyrosine dimers in recombinant α-synuclein

2015

Parkinson's disease is associated with fibril deposition in the diseased brain. Misfolding events of the intrinsically disordered synaptic protein α-synuclein are suggested to lead to the formation of transient oligomeric and cytotoxic species. The etiology of Parkinson's disease is further associated with mitochondrial dysfunction and formation of reactive oxygen species. Oxidative stress causes chemical modification of native α-synuclein, plausibly further influencing misfolding events. Here, we present evidence for the spontaneous formation of covalent di-tyrosine α-synuclein dimers in standard recombinant protein preparations, induced without extrinsic oxidative or nitrative agents. The…

chemistry.chemical_classificationReactive oxygen speciesParkinson's diseasealphasynucleinamyloids di-tyrosine dimers EOM Parkinson’s disease SAXSSAXSOxidative phosphorylationFibrilmedicine.disease_causeIndustrial and Manufacturing Engineeringchemistry.chemical_compoundα-synucleinMonomerchemistryBiochemistryCovalent bondmedicinedi-tyrosine dimersamyloidsTyrosineProtein secondary structureEOMOxidative stressResearch PaperIntrinsically Disordered Proteins
researchProduct

PGC-1α: a master gene that is hard to master

2012

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that favorably affects mitochondrial function. This concept is supported by an increasing amount of data including studies in PGC-1α gene-deleted mice, suggesting that PGC-1α is a rescue factor capable of boosting cell metabolism and promoting cell survival. However, this view has now been called into question by a recent study showing that adeno-associated virus-mediated PGC-1α overexpression causes overt cell degeneration in dopaminergic neurons. How is this to be understood, and can these seemingly conflicting findings tell us something about the role of PGC-1α in cell stress and in cont…

medicine.medical_specialtyModels NeurologicalSettore BIO/11 - Biologia MolecolareRNA-binding proteinBiologyMitochondrionSettore BIO/09 - FisiologiaMiceCellular and Molecular NeuroscienceHeat shock proteinInternal medicinemedicineAnimalsHomeostasisHumansReceptorMolecular BiologyTranscription factorHeat-Shock ProteinsMice KnockoutPharmacologyPGC-1α Mitochondria Dopaminergic neurons Transgenic animal Adenovirus Parkinson’s diseaseDopaminergic NeuronsDopaminergicRNA-Binding ProteinsParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaEndocrinologyCell metabolismNerve DegenerationTrans-ActivatorsMolecular MedicineNeuroscienceHomeostasisTranscription FactorsCellular and Molecular Life Sciences
researchProduct